Table 1.
Demographics of the studied cohort.
| Week 0 (Baseline) | Week 14 | |
|---|---|---|
| Number of samples (N) | 1315 | 198 |
| Median age at first dose [IQR], yr | 33 [23–47] | 33 [24–46] |
| Number of females (%) | 673 (51.2) | 86 (43.4) |
| Median disease duration at first dose [IQR], yr | 2.5 [0.7–9.0] | 2.0 [0.6–10.1] |
| Anti-TNFα treatment (n) | ||
| Infliximab (IFX) | 820 | 100 |
| Adalimumab (ADA) | 495 | 98 |
| Therapy outcome (n) | ||
| Primary non-response (PNR) | 258 | 33 |
| Response | 180 | 165 |
| Grey zone | 231 | / |
| Remission | 515 | / |
| N/A | 131 | / |
Week 0: first time point/baseline data collected before the first dose of anti-TNF therapy; Week 14—second time point data collected for the subset of patients immediately before the next scheduled anti-TNF injection/infusion.